Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 65.42 0.54 (0.83%) Market Cap: 12.47 Bil Enterprise Value: 12.14 Bil PE Ratio: 39.17 PB Ratio: 2.30 GF Score: 72/100

Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 03:40PM GMT
Release Date Price: $81.09 (-0.02%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Thank you, everyone, for joining us. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs, and we're pleased to have BioMarin with us today. We have Hank Fuchs, who is the President of Worldwide Research & Development and Chief Medical Officer as well. So Hank, with that, I think you wanted to make some opening remarks?

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Sure. Wow, that's loud. Better. BioMarin, just to remind people, a 21-year-old company. Unusual for a 21-year-old company and 7 products on the market in over 70 different countries and delivering each of these products, it's not just the first product -- it's not just the best product for the indication, the first product for the indication and the only product for the indication. So we've been a company known for making breakthrough advances in patients with very difficult-to-treat diseases and have very fundamental and profound impacts in those patients

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot